Category: New products
-
Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems.
-
“Dark Genome” Drug Discoverer Gains $37M in Early Funds
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University of Oxford medical school. Nucleome Therapeutics is seeking new treatments for…
-
Trial Shows Wearable Device Can Reduce Migraine
Results from a clinical trial show an electronic device worn on the arm can reduce migraine occurrences in people with history of the condition.
-
Trial Begins Testing RNA Hepatitis-B Treatment
A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease.
-
Hydrogel Biomaterials Company Raises $3M in Early Funds
A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round.
-
Gene Therapy Stimulates Missing Enzymes in Rare Disease
Results from a clinical trial show an experimental gene therapy for Krabbe disease is safe and produces enzymes missing in children with the rare disease.
-
RNA Cancer Immunotherapy Shown Feasible in Preclinical Test
Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors.
-
Nasal Spray Vaccines Get CEPI, NIH Funding
A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea.
-
Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test
A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria.
-
Start-Up Developing Efficient RNA Process, Raises $12M
A company formed earlier this year is commercializing a more efficient process for making synthetic RNA molecules and raising $12 million in seed funds.